Tenaya Therapeutics (TNYA) announced that it will present five abstracts at the upcoming American Society of Gene and Cell Therapy, ASGCT 2025, 28th Annual Meeting taking place May 13-17, 2025 in New Orleans, LA. The abstracts being presented at ASGCT 2025 capture the outcome of efforts to advance Tenaya’s core capabilities in novel capsid engineering, identification, design and optimization of cardiomyocyte-targeting genetic medicines, and manufacturing of adeno-associated virus gene therapies.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Strong Buy Recommendation for Tenaya Therapeutics Amid Promising Trial Results and Financial Stability
- Positive Outlook for Tenaya Therapeutics: Buy Rating Based on Gene Therapy Progress and Financial Stability
- Promising Advancements and Stable Financials: A Buy Rating for Tenaya Therapeutics
- Tenaya Therapeutics Reports Q1 2025 Financial Results
- Buy Rating for Tenaya Therapeutics Driven by Promising Clinical Developments and Strategic Restructuring